Arcutis Biotherapeutics, Inc. (ARQT)
收市後：
| 前收市價 | 5.54 |
| 開市 | 5.62 |
| 買盤 | 5.13 x 900 |
| 賣出價 | 5.34 x 800 |
| 今日波幅 | 5.28 - 5.66 |
| 52 週波幅 | 5.19 - 20.64 |
| 成交量 | |
| 平均成交量 | 980,590 |
| 市值 | 327.383M |
| Beta 值 (5 年，每月) | 0.64 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -5.27 |
| 業績公佈日 | 2023年11月06日 - 2023年11月10日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 41.88 |
InvestorPlace3 Biotech Stocks Due for a Massive Short Squeeze
Here’s a look at 3 biotech short squeeze candidates. For investors looking for short-term gains, technical analysis provides key insights on potential entry and exit points. However, over the years, various short-term trading strategies have emerged that deliver good results. Since 2021, exposure to stocks with high short interest has translated into massive returns in quick time. The reason for focus on biotech stock is the point that the sector has been largely depressed. There seems to be amp
InvestorPlace7 Short-Interest Stocks to Target for Explosive Gains
Ranking among the most speculative practices in the equities arena, deliberately bidding up short-interest stocks may generate wildly robust gains. At the same time, higher risks for the intrepid market participant also signifies substantial risks. Fundamentally, triggering emotions of panic undergird short-squeeze stocks. When bearish traders “attack” a security, they aim to profit from their value erosion. However, if the underlying security rises in value, they lose. Because no upside ceiling
BenzingaArcutis' Flagship Psoriasis Treatment Shows Sustained Efficacy, Clearance For Median Of 10 Months
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) announced new safety and efficacy durability data from its open-label Phase 2 long-term safety study of roflumilast cream (0.3%) in adults with chronic plaque psoriasis. Roflumilast cream 0.3% (Zoryve) is a once-daily steroid-free topical phosphodiesterase-4 inhibitor approved by the FDA in July 2022. The study showed that during the trial, 57.1% (n=185) of roflumilast cream-treated patients achieved an Investigator Global Assessment (IGA) score of clea
